NHS Cancer Jab Could Mean Patients Spend Hours Less in Hospital

NHS cancer jab could mean patients – For the first time, patients in the UK may soon receive a revolutionary treatment for cancer that drastically reduces the time spent in hospitals. The new injectable form of Keytruda, a pivotal immunotherapy drug, promises to cut the duration of the administration process by over 90% for thousands of individuals. This shift could not only ease the burden on healthcare staff but also empower patients to reclaim hours of their daily lives, potentially enabling them to pursue activities outside of clinical settings.

The Evolution of Keytruda Delivery

Keytruda, already a cornerstone in the treatment of multiple cancers, operates by harnessing the body’s immune system to combat malignant cells. Traditionally, NHS patients have received the drug through intravenous infusions, a process that involves preparing a sterile solution and delivering it via a drip. This method, which can take more than an hour in a hospital, has long been the standard for administering the medication. However, the introduction of an alternative injectable format marks a significant departure from this routine.

Until recently, the preparation of Keytruda required hospital pharmacy teams to meticulously assemble a solution under sterile conditions. The drug is then introduced into the bloodstream through a cannula, a procedure that often involves extended waiting times for patients. NHS England has now announced plans to transition to a more efficient method, where the same medication can be administered as a quick injection, taking just a few minutes. This change is expected to streamline operations and reduce the strain on hospital resources.

A Patient’s Perspective on the Change

Shirley Xerxes, a 86-year-old resident of St Albans, Hertfordshire, was among the first to benefit from the injectable version of Keytruda at the Mount Vernon Cancer Centre. Her experience highlights the tangible impact of the reform: “I was in the chair for a matter of minutes instead of an hour or more.” This reduction in treatment time, she noted, has transformed her ability to engage in everyday activities. “It’s made such a difference and gives me more time to live my life, including spending more time gardening,” she added.

The shift to injectable Keytruda is anticipated to affect approximately 14,000 patients in England annually. Most of these individuals are likely to transition to the new format, which simplifies the process for both patients and medical professionals. The drug is currently used to treat 14 different cancer types, including lung, head and neck, cervical, and breast cancers. The new injectable options, administered every three or six weeks depending on the diagnosis, could further enhance accessibility and convenience.

Immunotherapy and Its Scientific Foundations

Immunotherapy, the class of treatment Keytruda belongs to, works by disrupting the signals that cancer cells use to evade detection. Some scientists liken this to the disease donning an “invisibility cloak” by producing proteins that trick the immune system into ignoring it. By blocking these signals, the therapy enables the immune cells to identify and destroy cancerous cells more effectively.

This mechanism of action was recognized as groundbreaking, earning James Allison and Tasuku Honjo the Nobel Prize for Medicine in 2018. Keytruda, one of the earliest immunotherapy drugs to receive approval, initially targeted skin cancer before expanding its use to other forms of the disease. Now, it ranks as the world’s most lucrative prescription medicine, with global sales surpassing $30 billion in 2025.

Implications for NHS Operations

NHS England’s national clinical director for cancer, Prof Peter Johnson, emphasized the potential of the injectable variant to optimize treatment delivery. “Managing cancer care and regular hospital visits can be incredibly exhausting for patients,” he explained. “If we can deliver this in a much shorter timeframe, it not only frees up space in chemotherapy units but also opens the door to outpatient care, reducing the need for inpatient stays.”

The transition to this new method is part of a broader strategy to adapt cancer treatments for community-based care. By minimizing the time required for administration, hospitals can reallocate resources to other critical tasks, improving efficiency across the healthcare system. Additionally, the injectable form may allow for more flexible scheduling, accommodating patients’ preferences and reducing overall wait times.

Cost and Competition Considerations

While NHS England has not disclosed the exact cost of the injectable Keytruda, it is understood that the price will remain comparable to the current infusion method. This decision is part of a confidential agreement with Merck Sharp & Dohme (MSD), the US pharmaceutical company behind the drug. The financial success of Keytruda, with estimated sales of $180 billion since its launch a decade ago, underscores its importance to the healthcare sector.

However, the upcoming expiration of patents in 2028 (in the US) and 2031 (in Europe) may lead to the development of cheaper generic versions by rival firms. In the US, critics like Democratic Senator Elizabeth Warren have raised concerns that MSD’s introduction of the injectable form is partly aimed at delaying competition. Despite this, MSD maintains that the new format provides substantial benefits for hospitals, including reduced administration time and enhanced workflow efficiency.

As the NHS continues to innovate, the injectable Keytruda represents a key step toward more patient-centric care. The ability to administer the drug in a matter of minutes not only addresses logistical challenges but also aligns with the growing trend of outpatient treatment. By making the therapy more accessible, the NHS aims to improve the overall patient experience while maintaining the effectiveness of the treatment.

A Broader Shift in Cancer Care

This development follows the introduction of another immunotherapy drug, Opdivo or nivolumab, as an injectable option in some UK hospitals last year. The success of these changes has paved the way for further advancements in how immunotherapies are delivered. With the new Keytruda format, patients may no longer need to rely on prolonged hospital visits, allowing them to maintain a more active lifestyle while undergoing treatment.

Prof Johnson’s remarks highlight the transformative potential of this innovation. “We’re moving toward a future where patients can access high-quality care without the constraints of long hospital stays,” he said. The injectable variant could also reduce the pressure on chemotherapy units, which are often overwhelmed by the volume of patients requiring infusions. This shift is expected to ease the demand for inpatient facilities and support the expansion of community-based healthcare services.

While the initial focus is on improving patient convenience, the broader implications of the injectable format extend to the financial and operational aspects of the NHS. By reducing the time and resources needed for each treatment session, the healthcare system can allocate its efforts more effectively. This could lead to cost savings in the long term and improve the overall capacity to manage complex cancer care regimens.

As the NHS embraces these advancements, the injectable Keytruda serves as a testament to the evolving landscape of cancer treatment. Patients like Shirley Xerxes are already reaping the rewards of a more efficient process, and the potential for wider adoption could redefine how immunotherapy is delivered across the country. With continued innovation, the goal of making cancer care more accessible and less disruptive to patients’ lives appears increasingly achievable.